| human | Q5 |
| P496 | ORCID iD | 0000-0003-3761-1166 |
| P1153 | Scopus author ID | 6701768368 |
| P69 | educated at | Middle East Technical University | Q756126 |
| P108 | employer | Food and Drug Administration | Q204711 |
| Bilkent University | Q861904 | ||
| P106 | occupation | researcher | Q1650915 |
| Q46099646 | Antibiotic release from biodegradable PHBV microparticles. |
| Q43637686 | Biodegradable polyhydroxyalkanoate implants for osteomyelitis therapy: in vitro antibiotic release. |
| Q43367569 | Biosorption of phenol and 2-chlorophenol by Funalia trogii pellets. |
| Q34727344 | CpG DNA: recognition by and activation of monocytes |
| Q33797188 | CpG oligodeoxynucleotides adsorbed onto polylactide-co-glycolide microparticles improve the immunogenicity and protective activity of the licensed anthrax vaccine |
| Q58863984 | CpG-mediated changes in gene expression in murine spleen cells identified by microarray analysis |
| Q38722242 | Encapsulation of two different TLR ligands into liposomes confer protective immunity and prevent tumor development |
| Q40282581 | Immunogenicity and protective efficacy of the recombinant Pasteurella lipoprotein E and outer membrane protein H from Pasteurella multocida A:3 in mice. |
| Q39565656 | Immunostimulatory activity of polysaccharide-poly(I:C) nanoparticles. |
| Q37629412 | Impaired toll like receptor-7 and 9 induced immune activation in chronic spinal cord injured patients contributes to immune dysfunction. |
| Q43510167 | In vivo application of biodegradable controlled antibiotic release systems for the treatment of implant-related osteomyelitis. |
| Q58864001 | In vivo response to biodegradable controlled antibiotic release systems |
| Q96762926 | Mesenchymal stem cell derived extracellular vesicles: promising immunomodulators against autoimmune, autoinflammatory disorders and SARS-CoV-2 infection |
| Q96772901 | Modulation of immune responses using adjuvants to facilitate therapeutic vaccination |
| Q36370825 | Potential role of phosphatidylinositol 3 kinase, rather than DNA-dependent protein kinase, in CpG DNA-induced immune activation |
| Q58864010 | Properties and drug release behaviour of poly(3-hydroxybutyric acid) and various poly(3-hydroxybutyrate-hydroxyvalerate) copolymer microcapsules |
| Q56897952 | Reduction of CpG-induced arthritis by suppressive oligodeoxynucleotides |
| Q34175032 | Reduction of surgery-induced peritoneal adhesions by continuous release of streptokinase from a drug delivery system. |
| Q28646147 | Signal transduction pathways mediated by the interaction of CpG DNA with Toll-like receptor 9 |
| Q58864005 | Sulbactam-cefoperazone polyhydroxybutyrate-co- hydroxyvalerate (PHBV) local antibiotic delivery system:In vivo effectiveness and biocompatibility in the treatment of implant-related experimental osteomyelitis |
| Q38550441 | Synthesis and mechanical properties of interpenetrating networks of polyhydroxybutyrate-co-hydroxyvalerate and polyhydroxyethyl methacrylate. |
| Q58863970 | The effects of an insertion in the 5′UTR of the AMCase on gene expression and pulmonary functions |
| Q36360888 | Therapeutic potential of oligonucleotides expressing immunosuppressive TTAGGG motifs. |
Search more.